HHCP
HELP

Hilton Head Capital Partners’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Hilton Head Capital Partners’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$773 Hold
117
– – ﹤0.01% 849
2026
Q1 		$562 Hold
117
– – ﹤0.01% 907
2025
Q4 		$957 Buy
+117
New +$753 ﹤0.01% 830

Other funds holding HELP

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Hilton Head Capital Partners's HELP Position: Q2 2026 in Review

Hilton Head Capital Partners held its Helus Pharma Inc. Common Stock (HELP) position steady in Q2 2026 at 117 shares worth $773. The position accounts for ﹤0.01% of the portfolio, ranked #849.

Hilton Head Capital Partners first reported a position in HELP in Q4 2025 and has held it in 3 quarters since. The position peaked at $957 in Q4 2025. 99 funds tracked by Wall St. Rank hold HELP as of Q2 2026.

  • Hilton Head Capital Partners held 117 shares of Helus Pharma Inc. Common Stock worth $773 as of Q2 2026.
  • Hilton Head Capital Partners left its Helus Pharma Inc. Common Stock share count unchanged in Q2 2026.
  • Helus Pharma Inc. Common Stock made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #849 holding.
  • Hilton Head Capital Partners first reported a position in Helus Pharma Inc. Common Stock in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's Helus Pharma Inc. Common Stock position peaked at $957 in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.